Skip to main content
JIANGSU YAHONG MEDITECH CO., LTD. logo

JIANGSU YAHONG MEDITECH CO., LTD. — Investor Relations & Filings

Ticker · 688176 ISIN · CNE100005XW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 480 across all filing types
Latest filing 2026-05-20 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688176

About JIANGSU YAHONG MEDITECH CO., LTD.

https://asieris.cn/

Jiangsu Yahong Meditech Co., Ltd., operating globally as Asieris Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases. The company specializes in urology and women's health, addressing unmet medical needs through a pipeline of therapeutic and diagnostic solutions. Key assets include APL-1202, an oral MetAP2 inhibitor for bladder cancer, and APL-1702, a photodynamic therapy for cervical lesions. The firm also develops APL-1706, an imaging agent designed to improve the detection of bladder cancer. By integrating research, clinical development, and manufacturing capabilities, the company aims to provide comprehensive management strategies for patients worldwide.

Recent filings

Filing Released Lang Actions
江苏亚虹医药科技股份有限公司2025年年度股东会会议资料
AGM Information Classification · 98% confidence The document is a detailed “2025年年度股东会会议资料” (Annual General Meeting materials) including the meeting notice, agenda, proposals (e.g., board work report, profit distribution, audit reappointment), and instructions for shareholders. It is clearly a package of presentations and materials to be used at the company’s AGM, matching the “AGM Information” category.
2026-05-20 Chinese
江苏亚虹医药科技股份有限公司关于补选董事的公告
Regulatory Filings
2026-05-06 Chinese
中信证券股份有限公司关于江苏亚虹医药科技股份有限公司首次公开发行股票并在科创板上市之保荐总结报告书
Regulatory Filings Classification · 95% confidence The document is titled as a "保荐总结报告书" which translates to a "Sponsorship Summary Report" related to the initial public offering (IPO) and listing of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the STAR Market (科创板). It details the sponsorship work done by CITIC Securities, including due diligence, continuous supervision, and compliance with regulatory requirements during the IPO process and subsequent listing period. The document includes information about the issuance, fundraising, regulatory approvals, and ongoing supervision until the end of the statutory supervision period. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. It is a detailed report summarizing the sponsorship and supervision activities related to the IPO and listing process, which fits the category of a Regulatory Filing (RNS) as it is a compliance and regulatory document that does not fit other specific categories such as Annual Report, Earnings Release, or Capital Update. The document length is under 5,000 characters, but it is a substantive report, not just an announcement of a report publication. Therefore, the best classification is Regulatory Filings (RNS).
2026-04-29 Chinese
江苏亚虹医药科技股份有限公司关于作废部分已授予但尚未归属的限制性股票的公告
Remuneration Information Classification · 95% confidence The document is an official announcement from Jiangsu Yahong Pharmaceutical Technology Co., Ltd. regarding the cancellation of certain granted but unvested restricted stocks under the 2022 and 2024 restricted stock incentive plans. It details board meetings, approvals, and legal opinions related to the cancellation of these restricted stocks. The content focuses on corporate governance and compensation-related decisions, specifically about stock incentives and their cancellation. There is no financial statement, earnings data, or detailed financial analysis present. The document is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a proxy solicitation or voting result announcement. Instead, it is a formal announcement about management decisions on stock incentives, which falls under Remuneration Information filings that detail executive and director compensation matters, including stock incentive plans and cancellations.
2026-04-29 Chinese
北京市嘉源律师事务所关于江苏亚虹医药科技股份有限公司2022年及2024年限制性股票激励计划归属条件成就及作废部分限制性股票的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 and 2024 restricted stock incentive plans of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. It discusses the legal compliance, approval, authorization, and conditions of stock vesting and cancellation under these incentive plans. The document references relevant laws, regulations, and company approvals, and provides detailed information on the stock incentive plans' vesting conditions, performance assessments, and cancellations. It is a standalone legal opinion related to stock incentive plans and does not contain financial statements or earnings data. It is not an announcement of a report but a legal opinion document. This type of document fits best under the category of Regulatory Filings (RNS) as it is a compliance/legal disclosure related to stock incentive plans and their legal validation, not a financial report, management change, or earnings release.
2026-04-29 Chinese
江苏亚虹医药科技股份有限公司2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '江苏亚虹医药科技股份有限公司2026年第一季度报告' which translates to 'Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2026 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2026. The report explicitly states it is a quarterly report and includes unaudited financial statements for the period January to March 2026. The length of the document (over 14,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-04-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.